Irreversible Electroporation for Inferior Turbinate Reduction Ablation in Adults.

Authors

Narin Nard Carmel Neiderman, Codrut Sarafoleanu, Ionut Tanase, Mihai Alexandru Pascu, Desiderio Passali, Ulugbek Saidakramovich Khasanov, Ulugbek Nuridinovich Vokhidov, Eugenijus Lesinskas, Marius Polianskis, Avraham Abergel

Published in

International forum of allergy & rhinology. Oct 01, 2026. Epub Oct 01, 2026.

Abstract

Inferior turbinate hypertrophy is a common cause of nasal airway obstruction. An optimal surgical approach should provide effective volume reduction while preserving mucosal integrity and minimizing postoperative morbidity.
To evaluate the safety and efficacy of irreversible electroporation (IRE) for non-thermal ablation of inferior turbinate hypertrophy.
This prospective, multi-center, single-arm study included adult patients with symptomatic nasal obstruction due to inferior turbinate hypertrophy refractory to medical therapy. All patients underwent IRE turbinate reduction using the ENTire system. Outcomes were assessed using the Nasal Obstruction Symptom Evaluation (NOSE), Nasal Obstruction Visual Analog Scale (NO-VAS), and the 22-item Sino-Nasal Outcome Test (SNOT-22) at baseline and at 1 week, 1 month, and 3 months. Postoperative pain and clinical healing were also evaluated.
Forty-eight patients completed the study. Significant improvement was observed across all outcome measures. The mean NOSE score decreased from 74.38 ± 13.39 to 11.25 ± 9.20, the NO-VAS score from 69.55 ± 19.48 to 12.51 ± 11.81, and the SNOT-22 score from 33.06 ± 24.18 to 7.48 ± 10.37 at 3 months (all p < 0.0001). Improvement was evident at 1 week and progressed through follow-up. Postoperative pain was low. No major complications occurred, and transient mucosal changes resolved by 3 months.
IRE is a promising non-thermal, minimally invasive technique for inferior turbinate reduction, providing significant symptom improvement with low postoperative morbidity. Larger studies with longer follow-up are needed to confirm durability.

PMID:
42817616
Bibliographic data and abstract were imported from PubMed on 01 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.